CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity (Q40896781)

24 September 2017

CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity (English)

1 reference

24 September 2017

Iwahashi M

1

1 reference

24 September 2017

Milenic DE

2

1 reference

24 September 2017

Padlan EA

3

1 reference

24 September 2017

Bei R

4

1 reference

24 September 2017

Schlom J

5

1 reference

24 September 2017

Kashmiri SV

6

1 reference

24 September 2017

language of work or name

1 reference

1 October 1999

1 reference

24 September 2017

1 reference

24 September 2017

36

1 reference

24 September 2017

15-16

1 reference

24 September 2017

1079-1091

1 reference

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

The Protein Data Bank: a computer-based archival file for macromolecular structures

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Recombinant human IgA expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

The human immune response to the OKT3 monoclonal antibody is oligoclonal

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Expression of colorectal carcinoma-associated antigens in colonic polyps

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Assay for the detection of anti-idiotypic antibodies to monoclonal antibody b72.3

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Application of 1,1'-carbonyldiimidazole-activated agarose for the purification of proteins. II. The use of an activated matrix devoid of additional charged groups for the purification of thyroid proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

A general method for rapid site-directed mutagenesis using the polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Anatomy of the antibody molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Identification of specificity-determining residues in antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

A CDR-grafted (humanized) domain-deleted antitumor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

Tumor-associated glycoprotein (TAG-72) expression in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0161-5890%2899%2900094-2

1 reference

7 January 2021

10.1016/S0161-5890(99)00094-2

Identifiers

DOI

1 reference

24 September 2017

1 reference